Orion to Attend Bio Europe, March 20-22
Orion Biotechnologies will be attending the Bio Europe conference, this spring from March 20th to the 22nd. The conference is being held in Basel Switzerland, within 3 hours (by car)
Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
Orion Biotechnology is discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapeutics for the treatment of cancer and other serious diseases
Orion’s novel drug modality involves precision engineering ligands of small protein GPCRs, providing an enhanced solution to targeting previously-undrugged GPCRs. This approach is supported by one of the fastest drug discovery platforms in the industry and represents a large opportunity to discover and develop a new generation of GPCR-targeted medicines
CCR5 Inhibitor Program
Orion’s lead compound, OB-002, is a GPCR analog of CCL5 with best-in-class potency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Infectious Disease and Neuroinflammatory disorders.
Recognized
Leadership
Previous
Next
We will be at BioEquity Europe in May
The 23rd edition of BioEquity Europe is planned to begin May 14th in Dublin Ireland, and Orion Biotechnology will be there. Bio€quity Europe is the industry’s premier CEO and investor
Orion Biotechnology Presenting at the 2nd GPCR-Targeted Drug Discovery Summit in Boston
February 24, 2023
Ottawa, Canada, Feb. 16, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
Orion Biotechnology Publishes Whitepaper Highlighting the Importance and Challenges in Unlocking “Undruggable” GPCRs
February 24, 2023
Ottawa, Canada, Feb. 02, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
Orion Biotechnology Shares In Vivo Efficacy Data on its Latest Best-in-Class Drug Candidate
February 24, 2023
Ottawa, Canada, Dec. 01, 2022 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
Global Headquarters
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Switzerland
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Poland
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
